Not all HPV strains cause cancers due to differences in viral oncogene potency
the verdict
SUPPORTED
the evidence backs this
confidence 88/100
Scientific literature confirms that different human papillomavirus (HPV) strains vary widely in their oncogenic potential, largely due to differences in the potency and binding affinity of their E6 and E7 viral oncoproteins for host tumor suppressors.
Evidence for · 6
Human Papillomavirus E6 and E7: Proteins which deregulate the cell cycle
1995 · cited by 100
High-risk HPV E6 and E7 proteins uniquely bind and inactivate tumor suppressors p53 and Rb1, driving oncogenic transformation while lower-risk strains lack these potent transforming capabilities.
See more details
More for · 5
Human papilloma virus (HPV) mediated cancers: an insightful update.
2025 · cited by 0
The oncogenic potential of HPV is directly tied to the specific genotype and the potent activity of its E6 and E7 oncoproteins.
What are the essential determinants of human papillomavirus carcinogenesis?
2024 · cited by 0
The varying potency of high-risk versus lower-risk viral oncoproteins and their interactions with host targets are essential determinants of whether an HPV infection leads to carcinogenesis.
Transforming Properties of Beta-3 Human Papillomavirus E6 and E7 Proteins.
2020 · cited by 0
Studies on differing HPV strains (such as beta-3 types) demonstrate varying in vitro transforming properties and abilities to inactivate p53 and pRb pathways, confirming differences in oncogene potency across strains.
The role of human papillomavirus oncoproteins E6 and E7 in apoptosis.
2002 · cited by 0
The distinct oncogenic potential of high-risk human papillomaviruses is largely attributed to the potent ability of E6 and E7 proteins to disrupt cell cycle control and evade apoptosis.
Human papillomaviruses.
1994 · cited by 0
Specific viral genes (E6 and E7) of high-risk HPVs act as strong oncogenes, contrasting with other genotypes found primarily in benign proliferations.